Blood Reagents Antitrust Class Action Settles

July 19, 2018 by

Ortho-Clinical Diagnostic has agreed to pay $19.5 million to resolve a class action alleging that it conspired with another company to fix prices on the reagents used in blood tests. Ortho-Clinical’s $19.5 million will be combined with a $22 million settlement that Immucor Inc. agreed to pay to resolve allegations against it, bringing the total settlement fund to $41.5 million.

Under the proposed settlement, class members who purchased the reagent before Jan. 1, 2005, will receive a pro rata share of the fund and those who purchased the product after that date will receive $250.

The suits claimed that the companies engaged in a price-fixing conspiracy that began in 2000 at an annual meeting of the American Association of Blood Banks, which was attended by executives from both Ortho-Clinical and Immucor, the two leaders in the market for traditional blood reagents.

The case is In re Blood Reagents Antitrust Litigation, case number 2:09-md-02081, in the U.S. District Court for the Eastern District of Pennsylvania.

Steve Larson
An experienced trial lawyer who handles both hourly and contingent fee cases, Steve has expertise in class actions, consumer cases, antitrust litigation, securities litigation, corporate disputes, intellectual property disputes, unfair competition claims, employment matters, and disputes involving family wealth. Steve regularly represents individuals and businesses in federal and state court and has obtained class-wide recovery in multiple class actions. A veteran practitioner, Steve's clients value his creative approach to resolving complex litigation matters.

Legal Disclaimer

The information contained in this blog does not constitute legal advice, and does not create an attorney-client relationship. We make no claims, promises or guarantees about the accuracy, completeness, or adequacy of the information contained in or linked to this blog.